Robert C. Flanigan, MD

Urology

Professor
Department Chairperson, Urology

Languages Spoken

English

Clinical Expertise

  • Bladder Cancer
  • Kidney Cancer
  • Testicular Cancer

Medical Education

Medical School
Case Western Reserve University School of Medicine
Residency
University Hospitals of Cleveland/Case Western Reserve University - Urology

Board Certification

American Board of Urology

Research

  • Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6 630 Men, Catalona, W. J.; Richie, J. P.; Ahmann, F. R.; Hudson, M. A.; Scardino, P. T.; Flanigan, R. C.; DeKernion, J. B.; Ratliff, T. L.; Kavoussi, L. R.; Dalkin, B. L.; Waters, W. B.; MacFarlane, M. T.; Southwick, P. C., The Journal of urology
  • Incidence of Adverse Contrast Reaction Following Nonintravenous Urinary Tract Imaging Blackwell, R. H.; Kirshenbaum, E. J.; Zapf, M. A. C.; Kothari, A. N.; Kuo, P. C.; Flanigan, R. C.; Gupta, G. N., European urology focus
  • Early Intervention during Acute Stone Admissions: Revealing "The Weekend Effect" in Urological Practice Blackwell, R. H.; Barton, G. J.; Kothari, A. N.; Zapf, M. A.; Flanigan, R. C.; Kuo, P. C.; Gupta, G. N., The Journal of urology
View All ResearchShow Less
  • PLK-1 Silencing in Bladder Cancer by siRNA Delivered With Exosomes Greco, K. A.; Franzen, C. A.; Foreman, K. E.; Flanigan, R. C.; Kuo, P. C.; Gupta, G. N., Urology
  • Urinary incontinence and diuretic avoidance among adults with chronic kidney disease Patel, M.; Vellanki, K.; Leehey, D. J.; Bansal, V. K.; Brubaker, L.; Flanigan, R.; Koval, J.; Wadhwa, A.; Balasubramanian, N.; Sandhu, J.; Kramer, H., International Urology and Nephrology
  • A primer on clinical trial design Ellimoottil, C.; Vijan, S.; Flanigan, R. C., Urologic oncology
  • New Onset Postoperative Atrial Fibrillation Predicts Long-Term Cardiovascular Events Following Radical Cystectomy Blackwell, R. H.; Ellimoottil, C.; Bajic, P.; Kothari, A.; Zapf, M.; Kliethermes, S.; Flanigan, R. C.; Quek, M. L.; Kuo, P. C.; Gupta, G. N., The Journal of urology
  • Urinary Exosomes: The Potential for Biomarker Utility Intercellular Signaling and Therapeutics in Urological Malignancy, Franzen, C. A.; Blackwell, R. H.; Foreman, K. E.; Kuo, P. C.; Flanigan, R. C.; Gupta, G. N., The Journal of urology
  • Urothelial cells undergo epithelial-to-mesenchymal transition after exposure to muscle invasive bladder cancer exosomes Franzen, C. A.; Blackwell, R. H.; Todorovic, V.; Greco, K. A.; Foreman, K. E.; Flanigan, R. C.; Kuo, P. C.; Gupta, G. N., Oncogenesis
  • New modalities for evaluation and surveillance of complex renal cysts Ellimoottil, C.; Greco, K. A.; Hart, S.; Patel, T.; Sheikh, M. M.; Turk, T. M.; Flanigan, R. C., The Journal of urology
  • Seeking a standard for adequate pathologic lymph node staging in primary bladder carcinoma Wang, L.; Mudaliar, K.; Mehta, V.; Barkan, G. A.; Quek, M. L.; Flanigan, R. C.; Picken, M. M., Virchows Archiv : an international journal of pathology
  • Acute acalculous cholecystitis after radical cystectomy: a report of two cases Greco, K. A.; Flanigan, R. C.; Quek, M. L., International journal of urology : official journal of the Japanese Urological Association
  • An Analysis of Leukapheresis and central venous catheter use in the randomized placebo controlled, phase 3 IMPACT trial of Sipuleucel-T for metastatic castrate resistant prostate cancer, Flanigan, R. C.; Polcari, A. J.; Shore, N. D.; Price, T. H.; Sims, R. B.; Maher, J. C.; Whitmore, J. B.; Corman, J. M., The Journal of urology
  • How to prepare and present scientific manuscripts in English Hannick, J. H.; Flanigan, R. C., International journal of urology : official journal of the Japanese Urological Association
  • Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer Rao, M. V.; Ellimoottil, C.; Sondej, T.; Flanigan, R. C.; Quek, M. L., Urologic oncology
  • Legends in urology Flanigan, R. C., The Canadian journal of urology
  • Radical Cystectomy after BCG Immunotherapy for High-Risk Nonmuscle-Invasive Bladder Cancer in Patients with Previous Prostate Radiotherapy Rao, M. V.; Quek, M. L.; Jayram, G.; Ellimoottil, C.; Sondej, T.; Hugen, C. M.; Flanigan, R. C.; Steinberg, G. D., ISRN urology
  • Renal lymph nodes for tumor staging: appraisal of 871 nephrectomies with examination of hilar fat Mehta, V.; Mudaliar, K.; Ghai, R.; Quek, M. L.; Milner, J.; Flanigan, R. C.; Picken, M. M., Archives of Pathology & Laboratory Medicine
  • Predictors of Gleason Score (GS) upgrading on subsequent prostatectomy: a single Institution study in a cohort of patients with GS 6 Mehta, V.; Rycyna, K.; Baesens, B. M.; Barkan, G. A.; Paner, G. P.; Flanigan, R. C.; Wojcik, E. M.; Venkataraman, G., INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
  • Prognostic variables and nomograms for renal cell carcinoma Flanigan, R. C.; Polcari, A. J.; Hugen, C. M., International Journal of Urology
  • Vanishing prostate cancer on radical prostatectomy (RP) in the PSA era: incidence and follow-up data from a cohort of 1 060 patients between 1998 and 2010, Mehta, V.; Mehrotra, S.; Flanigan, R. C.; Wojcik, E. M.; Venkataraman, G., Virchows Archiv : an international journal of pathology
  • Long-term outcomes of salvage radiotherapy for PSA-recurrent prostate cancer: validation of the Stephenson nomogram. Hugen, C. M.; Polcari, A. J.; Quek, M. L.; Garza, R. P.; Fitzgerald, M. P.; Flanigan, R. C., World journal of urology
  • Risk factors for recurrence following radical cystectomy for pathologic node negative bladder cancer. Hugen, C. M.; Polcari, A. J.; Fitzgerald, M. P.; Dauw, C.; Flanigan, R. C.; Quek, M. L., Journal of surgical oncology
  • The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function. Mulhall, J. P.; Parker, M.; Waters, B. W.; Flanigan, R. C., BJU international
  • Comparison of open and robot-assisted pelvic lymphadenectomy for prostate cancer. Polcari, A. J.; Hugen, C. M.; Sivarajan, G.; Woods, M. E.; Paner, G. P.; Flanigan, R. C.; Quek, M. L., Journal of Endourology
  • Morphometric signature differences in nuclei of Gleason pattern 4 areas in Gleason 7 prostate cancer with differing primary grades on needle biopsy. Venkataraman, G.; Rycyna, K.; Rabanser, A.; Heinze, G.; Baesens, B. M.; Ananthanarayanan, V.; Paner, G. P.; Barkan, G. A.; Flanigan, R. C.; Wojcik, E. M., Journal of Urology
  • Penile rehabilitation following radical prostatectomy: predicting success Muller, A.; Parker, M.; Waters, B. W.; Flanigan, R. C.; Mulhall, J. P., The journal of sexual medicine
  • Persistent erectile dysfunction following radical prostatectomy: the association between nerve-sparing status and the prevalence and chronology of venous leak. Tal, R.; Valenzuela, R.; Aviv, N.; Parker, M.; Waters, W. B.; Flanigan, R. C.; Mulhall, J. P., Journal of Sexual Medicine
  • Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. Lara, P. N., Jr; Tangen, C. M.; Conlon, S. J.; Flanigan, R. C.; Crawford, E. D., Journal of Urology
  • Renal FNA-based typing of renal masses remains a useful adjunctive modality: evaluation of 31 renal masses with correlative histology. Masoom, S.; Venkataraman, G.; Jensen, J.; Flanigan, R. C.; Wojcik, E. M., Cytopathology
  • The role of cytoreductive nephrectomy in the era of molecular targeted therapy Polcari, A. J.; Gorbonos, A.; Milner, J. E.; Flanigan, R. C., International Journal of Urology
  • The role of lymph node density in bladder cancer prognostication Quek, M. L.; Flanigan, R. C., World journal of urology
  • Words of wisdom. Re: Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. Flanigan, R. C.; Polcari, A., European urology
  • An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre open-label, randomised phase III trial., Wood, C.; Srivastava, P.; Bukowski, R.; Lacombe, L.; Gorelov, A. I.; Gorelov, S.; Mulders, P.; Zielinski, H.; Hoos, A.; Teofilovici, F.; Isakov, L.; Flanigan, R. C.; Figlin, R.; Gupta, R.; Escudier, B., Lancet
  • Analysis of chromosome 1p abnormalities in renal oncocytomas by loss of heterozygosity studies: correlation with conventional cytogenetics and fluorescence in situ hybridization. Picken, M. M.; Chyna, B.; Flanigan, R. C.; Lee, J. M., American Journal of Clinical Pathology
  • Chromosome 1 analysis in chromophobe renal cell carcinomas with tissue microarray (TMA)-facilitated fluorescence in situ hybridization (FISH) demonstrates loss of 1p/1 which is also present in renal oncocytomas. Meyer, P. N.; Cao, Y.; Jacobson, K.; Krausz, T.; Flanigan, R. C.; Picken, M. M., Diagnostic Molecular Pathology
  • High incidence of aneuploidy in low grade urothelial carcinomas Alvarez, A.; Venkataraman, G.; Quek, M.; Flanigan, R.; Wojcik, E., International Journal of Urology
  • Maintenance of Certification: what is it and why is it happening. Flanigan, R. C.; Howards, S. S., AUA Update Series
  • Prostate specific antigen (PSA)-based screening. Suzuki, H.; Flanigan, R. C.; Okuyama, A., International Journal of Urology
  • Renal cell carcinoma in two patients with crossed fused ectopic kidneys. Davis, C. M.; Rao, M. V.; Flanigan, R. C.; Quek, M. L., Urologia internationalis
  • The importance of histology and cytogenetics in decision making for renal cell carcinoma. Garcia, J. G.; Picken, M. M.; Flanigan, R. C., World journal of urology
  • Urine cytology for surveillance of the remnant urothelium after radical cystectomy and urinary diversion Fok, C. S.; Liu, L.; Venkataraman, G.; Barkan, G. A.; Flanigan, R. C.; Wojcik, E. M.; Quek, M. L., Journal of Urology
  • High incidence of chromosome 1 abnormalities in a series of 27 renal oncocytomas: cytogenetic and fluorescence in situ hybridization studies. Paner, G. P.; Lindgren, V.; Jacobson, K.; Harrison, K.; Cao, Y.; Campbell, S. C.; Flanigan, R. C.; Picken, M. M., Archives of Pathology & Laboratory Medicine
  • Identification of patients with low-risk for aneuploidy: comparative discriminatory models using linear and machine-learning classifiers in prostate cancer. Venkataraman, G.; Heinze, G.; Holmes, E. W.; Ananthanarayanan, V.; Bostwick, D. G.; Paner, G. P.; Bradford-De La garza, C. M.; Brown, H. G.; Flanigan, R. C.; Wojcik, E. M., Prostate
  • Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Nagda, S. N.; Mohideen, N.; Lo, S. S.; Khan, U.; Dillehay, G.; Wagner, R.; Campbell, S.; Flanigan, R. C., International journal of radiation oncology, biology, physics
  • Prostatic fatty acids and cancer recurrence after radical prostatectomy for early-stage prostate cancer. Freeman, V. L.; Flanigan, R. C.; Meydani, M., Cancer Causes & Control
  • Renal tumors: the good the bad, and the ugly, Flanigan, R. C., International Journal of Urology
  • Self-reported volume of radical prostatectomies among urologists in the USA. Denberg, T. D.; Flanigan, R. C.; Kim, F. J.; Hoffman, R. M.; Steiner, J. F., BJU international
  • The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer. Kositsawat, J.; Flanigan, R. C.; Meydani, M.; Choi, Y. K.; Freeman, V. L., Journal of Urology
  • Validation of World Health Organization/International Society of Urologic Pathology 2004 classification schema for bladder urothelial carcinomas using quantitative nuclear morphometry: identification of predictive features using bootstrap method. Kapur, U.; Antic, T.; Venkataraman, G.; Durazo-Arvizu, R. A.; Quek, M. M.; Flanigan, R. C.; Wojcik, E. M., Urology
  • Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults. Meyer, P. N.; Clark, J. I.; Flanigan, R. C.; Picken, M. M., American Journal of Clinical Pathology
  • Androgen receptor levels are increased by interferons in human prostate stromal and epithelial cells. Basrawala, Z.; Alimirah, F.; Xin, H.; Mohideen, N.; Campbell, S. C.; Flanigan, R. C.; Choubey, D., Oncogene
  • Morphometric sum optical density as a surrogate marker for ploidy status in prostate cancer: an analysis in 180 biopsies using logistic regression and binary recursive partitioning. Venkataraman, G.; Ananthanarayanan, V.; Paner, G. P.; He, R.; Masoom, S.; Sinacore, J.; Flanigan, R. C.; Wojcik, E. M., Virchows Archiv
  • Radical cystectomy with extended lymphadenectomy in the presence of a pelvic kidney. Quek, M. L.; Basrawala, Z.; McClung, C.; Flanigan, R. C., Urology
  • Subspecialty certification in urology: a US perspective. Flanigan, R. C., Nature Clinical Practice Urology
  • The influence of patient race and social vulnerability on urologist treatment recommendations in localized prostate carcinoma. Denberg, T. D.; Kim, F. J.; Flanigan, R. C.; Fairclough, D.; Beaty, B. L.; Steiner, J. F.; Hoffman, R. M., Medical care
  • The relationship between threat appraisal and social constraints in cancer survivors and their spouses. Herzer, M.; Zakowski, S. G.; Flanigan, R. C.; Johnson, P., Journal of Behavioral Medicine
  • Urothelial-cell carcinoma and solitary kidney: outcomes with renal-sparing management. Milner, J. E.; Voelzke, B. B.; Flanigan, R. C.; Sharma, S. K.; Perry, K. T.; Turk, T. M., Journal of Endourology
  • Utility of prostate biopsy morphometric sum optical density for identifying extraprostatic extension on subsequent prostatectomy. Bargaje, A.; Venkataraman, G.; Flanigan, R. C.; Wojcik, E. M.; Ananthanarayanan, V., Analytical & Quantitative Cytology & Histology
  • A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109 Van Veldhuizen, P. J.; Faulkner, J. R.; Lara, P. N., Jr; Gumerlock, P. H.; Goodwin, J. W.; Dakhil, S. R.; Gross, H. M.; Flanigan, R. C.; Crawford, E. D.; Southwest Oncology Group, CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • Does lymphadenectomy improve cancer-specific survival in patients with renal cell carcinoma?. Flanigan, R. C., Nature Clinical Practice Urology
  • Renal neoplasms in younger adults: analysis of 112 tumors from a single institution according to the new 2004 World Health Organization classification and 2002 American Joint Committee on Cancer Staging System. Cao, Y.; Paner, G. P.; Perry, K. T.; Flanigan, R. C.; Campbell, S. C.; Picken, M. M., Archives of Pathology & Laboratory Medicine
  • Risk assessment for occult malignancy in the prostate before radical cystectomy. Kefer, J. C.; Voelzke, B. B.; Flanigan, R. C.; Wojcik, E. M.; Waters, W. B.; Campbell, S. C., Urology
  • The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. Mulhall, J.; Land, S.; Parker, M.; Waters, W. B.; Flanigan, R. C., Journal of Sexual Medicine
  • The utility of screening renal ultrasonography: identifying renal cell carcinoma in an elderly asymptomatic population. Malaeb, B. S.; Martin, D. J.; Littooy, F. N.; Lotan, Y.; Waters, W. B.; Flanigan, R. C.; Koeneman, K. S., BJU international
  • Cytogenetic analysis of a series of 13 renal oncocytomas. Lindgren, V.; Paner, G. P.; Omeroglu, A.; Campbell, S. C.; Waters, W. B.; Flanigan, R. C.; Picken, M. M., Journal of Urology
  • Cytologic features of recurrent lymphoma involving the urinary bladder. Quinn, A. M.; Flanigan, R. C.; Sienko, A.; Wojcik, E. M., Diagnostic cytopathology
  • Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis Flanigan, R. C.; Mickisch, G.; Sylvester, R.; Tangen, C.; Van Poppel, H.; Crawford, E. D., Journal of Urology
  • Debulking nephrectomy in metastatic renal cancer Flanigan, R. C., Clinical Cancer Research
  • Innovations and challenges in renal cancer: consensus statement from the first international conference Atkins, M. B.; Avigan, D. E.; Bukowski, R. M.; Childs, R. W.; Dutcher, J. P.; Eisen, T. G.; Figlin, R. A.; Finke, J. H.; Flanigan, R. C.; George, D. J.; Goldberg, S. N.; Gordon, M. S.; Iliopoulos, O.; Kaelin, W. G., Jr; Linehan, W. M.; Lipton, A.; Motzer, R. J.; Novick, A. C.; Stadler, W. M.; Teh, B. T.; Yang, J. C.; King, L., Clinical Cancer Research
  • Inverse association between prostatic polyunsaturated fatty acid and risk of locally advanced prostate carcinoma. Freeman, V. L.; Meydani, M.; Hur, K.; Flanigan, R. C., Cancer
  • Metastatic juxtaglomerular cell tumor in a 52-year-old man. Duan, X.; Bruneval, P.; Hammadeh, R.; Fresco, R.; Eble, J. N.; Clark, J. I.; Vigneswaran, W. T.; Flanigan, R. C.; Picken, M. M., American Journal of Surgical Pathology
  • Pathologic quiz case: renal mass in an otherwise healthy man. Epithelioid angiomyolipoma. Rubinas, T. C.; Flanigan, R. C.; Picken, M. M., Archives of Pathology & Laboratory Medicine
  • Renal tumor with overlapping distal nephron morphology and karyotype. Lindgren, V.; Paner, G. P.; Flanigan, R. C.; Clark, J. I.; Campbell, S. C.; Picken, M. M., Archives of Pathology & Laboratory Medicine
  • Renal tumors in young adults Eggener, S. E.; Rubenstein, J. N.; Smith, N. D.; Nadler, R. B.; Kontak, J.; Flanigan, R. C.; Waters, W. B.; Picken, M.; Campbell, S. C., Journal of Urology
  • The prevalence and nature of orgasmic dysfunction after radical prostatectomy. Barnas, J. L.; Pierpaoli, S.; Ladd, P.; Valenzuela, R.; Aviv, N.; Parker, M.; Waters, W. B.; Flanigan, R. C.; Mulhall, J. P., BJU international
  • Written emotional disclosure buffers the effects of social constraints on distress among cancer patients. Zakowski, S. G.; Ramati, A.; Morton, C.; Johnson, P.; Flanigan, R. C., Health Psychology
  • Cytoreductive nephrectomy in metastatic renal cancer Flanigan, R. C., Current urology reports
  • Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture. Unger, J. M.; LeBlanc, M.; Crowley, J. J.; Grossman, H. B.; Natale, R. B.; Wozniak, A. J.; Berenson, J. R.; List, A. F.; Peters, W. A., 3rd; Flanigan, R. C.; Macdonald, J. S.; Al-Sarraf, M.; Thompson, I. M.; Coltman, C. A., Jr, Journal of Clinical Oncology
  • Heat Shock Proteins: Biology and Potential Clinical Application. Flanigan, R. C., Kidney Cancer
  • Metastatic renal cell carcinoma Flanigan, R. C.; Campbell, S. C.; Clark, J. I.; Picken, M. M., Current Treatment Options in Oncology
  • Nephrectomy in metastatic renal cell carcinoma Campbell, S. C.; Flanigan, R. C.; Clark, J. I., Current Treatment Options in Oncology
  • Radical retropubic prostatectomy - what works for me Flanigan, R. C., Contemporary Urology
  • Role of nephrectomy in metastatic kidney cancer Yonover, P. M.; Sharma, S. K.; Flanigan, R. C., Cancer Treatment & Research
  • Social barriers to emotional expression and their relations to distress in male and female cancer patients. Zakowski, S. G.; Harris, C.; Krueger, N.; Laubmeier, K. K.; Garrett, S.; Flanigan, R. C.; Johnson, P., British Journal of Health Psychology
  • Effect of prostatic edema on CT-based postimplant dosimetry. Dogan, N.; Mohideen, N.; Glasgow, G. P.; Keys, K.; Flanigan, R. C., International journal of radiation oncology, biology, physics
  • Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with the recovery of erectile function. Mulhall, J. P.; Slovick, R.; Hotaling, J.; Aviv, N.; Valenzuela, R.; Waters, W. B.; Flanigan, R. C., Journal of Urology
  • Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a southwest oncology group study. Whitehead, R. P.; Lew, D.; Flanigan, R. C.; Weiss, G. R.; Roy, V.; Glode, M. L.; Dakhil, S. R.; Crawford, E. D., Journal of Immunotherapy
  • Role of nephrectomy in metastatic renal cell carcinoma. Flanigan, R. C.; Yonover, P. M.; Campbell, S. C., AUA Update Series
  • Survival advantage of Interleukin-2 over Interferon Immunotherapy when combine with cytoreductive nephrectomy based on SWOP 8949-matched populations. Pantuck, A. J.; Zisman, A.; Chao, D.; Dorey, F.; Flanigan, R. C.; DeKernion, J. B.; Figlin, R.; Belldegrun, A., Journal of Urology
  • The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. Gatenby, R. A.; Gawlinski, E. T.; Tangen, C. M.; Flanigan, R. C.; Crawford, E. D., Cancer research
  • Alterations in peripheral B cells and B cell progenitors following androgen ablation in mice. Ellis, T. M.; Moser, M. T.; Le, P. T.; Flanigan, R. C.; Kwon, E. D., International immunology
  • Assessing the effect of fatty acids on prostate carcinogenesis in humans: does self-reported dietary intake rank prostatic exposure correctly?. Freeman, V. L.; Meydani, M.; Yong, S.; Pyle, J.; Durazo-Arvizu, R. A.; Liao, Y.; Flanigan, R. C.; Waters, W. B., American Journal of Clinical Nutrition
  • Is a 1-CM margin necessary during nephron-sparing surgery for renal cell carcinoma?. Piper, N. Y.; Bishoff, J. T.; Magee, C.; Haffron, J. M.; Flanigan, R. C.; Mintiens, A.; Van Poppel, H. P.; Thompson, I. M.; Harmon, W. J., Urology
  • Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. Flanigan, R. C.; Salmon, S. E.; Blumenstein, B. A.; Bearman, S. I.; Roy, V.; McGrath, P. C.; Caton, J. R., Jr; Munshi, N.; Crawford, E. D., New England Journal of Medicine
  • Phase II evaluation of suramin in advanced renal cell carcinoma. A Southwest Oncology Group study Schroder, L. E.; Lew, D.; Flanigan, R. C.; Eisenberger, M. A.; Seay, T. E.; Hammond, N.; Needles, B. M.; Crawford, E. D., Urologic oncology
  • T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Mercader, M.; Bodner, B. K.; Moser, M. T.; Kwon, P. S.; Park, E. S.; Manecke, R. G.; Ellis, T. M.; Wojcik, E. M.; Yang, D.; Flanigan, R. C.; Waters, W. B.; Kast, W. M.; Kwon, E. D., Proceedings of the National Academy of Sciences of the United States of America
  • The role of radical nephrectomy in metastatic renal cell carcinoma Flanigan, R. C.; Yonover, P. M., Seminars in urologic oncology
  • The role of resection for patients with renal carcinoma Flanigan, R. C.; Yonover, P. M., Current oncology reports
  • Bacillus Calmette-Guerin. Is monthly maintenance an option for transitional cell carcinoma of the bladder? Flanigan, R. C.; DeLaurentis, D. A.; Waters, W. B.; Kunz, K., Urologic oncology
  • Comparative analysis of DNA flow cytometry and cytology of bladder washings: review of discordant cases. Bakhos, R.; Shankey, T. V.; Flanigan, R. C.; Fisher, S.; Wojcik, E. M., Diagnostic cytopathology
  • Comparison of percent free PSA PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging., Catalona, W. J.; Southwick, P. C.; Slawin, K. M.; Partin, A. W.; Brawer, M. K.; Flanigan, R. C.; Patel, A.; Richie, J. P.; Walsh, P. C.; Scardino, P. T.; Lange, P. H.; Gasior, G. H.; Loveland, K. G.; Bray, K. R., Urology
  • Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study Elias, L.; Lew, D.; Figlin, R. A.; Flanigan, R. C.; Thompson, M. E.; Triozzi, P. L.; Belt, R. J.; Wood, D. P., Jr; Rivkin, S. E.; David, E., Cancer
  • Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial. Catalona, W. J.; Partin, A. W.; Slawin, K. M.; Naughton, C. K.; Brawer, M. K.; Flanigan, R. C.; Richie, J. P.; Patel, A.; Walsh, P. C.; Scardino, P. T.; Lange, P. H.; deKernion, J. B.; Southwick, P. C.; Loveland, K. G.; Parson, R. E.; Gasior, G. H., Urology
  • Primary localized amyloidosis of the ureter and bladder managed by ileal interposition. Hafron, J. M.; Flanigan, R. C., Techniques in urology
  • Prostatic levels of fatty acids and the histopathology of localized prostate cancer. Freeman, V. L.; Meydani, M.; Yong, S.; Pyle, J.; Flanigan, R. C.; Waters, W. B.; Wojcik, E. M., Journal of Urology
  • Renal cell carcinoma with metastasis to the thyroid gland Pitale, S. U.; Sizemore, G. W.; Bakhos, R.; DeJong, S. A.; Flanigan, R. C.; Emanuele, N. V., Urologic oncology
  • Should radical nephrectomy be performed in the face of surgically incurable disease? Yonover, P. M.; Flanigan, R. C., Current opinion in urology
  • The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: implications for treatment selection. Gao, X.; Mohideen, N.; Flanigan, R. C.; Waters, W. B.; Wojcik, E. M.; Leman, C. R., Journal of Urology